Digital health start-up Amalgam Rx launched today with the release of iSage Rx, which it touts as the 1st FDA 510(k)-cleared, prescription mobile app for insulin titration. The app allows physicians to choose from clinically-validated basal insulin algorithms and tailor them to the needs of their patients with Type II diabetes. Patients record their blood glucose […]
Pharmaceuticals
scPharmaceuticals names Tucker as CEO | Personnel Moves – May 1, 2017
scPharmaceuticals said in late April that it named pharma-veteran John Tucker as president & CEO, effective immediately. Tucker was also elected to the company’s board of directors. Tucker formerly served as CEO of Alcresta, where he led regulatory and financing strategies for the company’s 1st product approval and launch. He also worked as Incline Therapeutics’ […]
Aeterna shares tumble after cancer-killing agent fails in Phase III trial
Shares in Aeterna Zentaris (NSDQ:AEZS) fell more than -50% this morning after the company said that the Phase III trial of Zoptrex did not meet its primary endpoint in women with locally advanced, recurrent or metastatic endometrial cancer. The ZoptEC pivotal trial was designed to evaluate the safety and efficacy of a hybrid molecule made up […]
Wireless power source could enable ingestible drug delivery devices
Researchers from the Massachusetts Institute of Technology, Brigham and Women’s Hospital and the Charles Stark Draper Laboratory have developed the means to wirelessly power electronic devices that stay in the digestive tract indefinitely. The team suggests that these devices could be used as sensors in the GI tract or carry drugs to be delivered over […]
H&T Presspart, Hovione ink commercialization deal for inhaler tech
H&T Presspart said this week that it acquired the global rights to Hovione Technology‘s capsule-based dry powder inhaler. The company launched a next-gen version of the inhaler called PowdAir Plus at this year’s Respiratory Drug Delivery Europe. The PowdAir Plus device is made of plastic and its 4-component design lessens manufacturing, assembly and production costs, according […]
Sanofi Q1 earnings top estimates, diabetes sales fall
Shares in Sanofi (NYSE:SNY) rose today after the company beat expectations on Wall Street with its 1st quarter results. The French company posted profits of $5.7 billion on sales of $8.65 billion for the 3 months ended March 31, for bottom-line growth of 413.5% on sales growth of 11.2% compared with the same period last year. […]
Allergan closes $2.48B Zeltiq acquisition
Allergan (NYSE:AGN) said today that it closed its $2.48 billion acquisition of Zeltiq Aesthetics Inc. (NSDQ:ZLTQ) and its portfolio of body-contouring products. Zeltiq’s FDA-approved CoolSculpting system uses a cooling mechanism to reduce the appearance of fat which has not responded to diet or exercise, without disturbing surrounding tissue. According to the deal, Allergan agreed to […]
United Therapeutics launches $250m share repurchase program
United Therapeutics (NSDQ:UTHR) said today that its board of directors approved the repurchase of up to $250 million of the biotech’s common stock. The share repurchase program is effective immediately and United said it will stay open until the end of 2017. The company can make purchases in the open market, accelerated share repurchases or in privately […]
Tandem misses on Q1 earnings, beats rev estimates
Shares in Tandem Diabetes (NSDQ:TNDM) fell today after the medical device maker missed earnings expectations on Wall Street with its 1st quarter results, but beat revenue estimates. The San Diego-based company posted losses of -$23.8 million, or -75¢ per share, on sales of $18.9 million for the 3 months ended March 31, for bottom-line loss of -13.9% […]
Novartis slapped with $49m fine over kickbacks
South Korea regulators said today that it fined Swiss drugmaker Novartis (NYSE:NVS) $48.8 million for offering doctors kickbacks in exchange for recommending the company’s drugs to patients. The Ministry of Health and Welfare also decided to suspend insurance coverage of 9 variations of 2 drugs, including the Alzheimer’s drug Exelon, for 6 months, according to Reuters. […]